ORIGINAL ARTICLE
A rare CD5-positive subgroup of diffuse large B-cell lymphoma – clinical, morphological and immunophenotypic features in Polish patients
1
Department of Pathology and Laboratory Diagnostics, Maria Skłodowska-Curie Institute and Oncology Centre,
Warsaw, Poland
2
Department of Pathology, Center for Biostructure Research, Medical University of Warsaw, Warsaw, Poland
3
Department of Lymphoid Malignancies, Maria Skłodowska-Curie Institute and Oncology Centre, Warsaw, Poland
4
Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
Submission date: 2016-02-16
Final revision date: 2016-04-06
Acceptance date: 2016-05-24
Publication date: 2016-11-25
Corresponding author
Nina Woźnialis
Department of Pathology and Laboratory Diagnostics Maria Skłodowska-Curie Institute and Oncology Centre Roentgena 5 02-781 Warsaw, Poland
Department of Pathology and Laboratory Diagnostics Maria Skłodowska-Curie Institute and Oncology Centre Roentgena 5 02-781 Warsaw, Poland
Pol J Pathol 2016;67(3):235-243
KEYWORDS
TOPICS
ABSTRACT
The aim of the study was to assess the incidence of CD5-positive diffuse large B-cell lymphoma (DLBCL) in the Polish population and to describe its morphologic and clinical characteristics. The study included 36 patients with CD5-positive DLBCL, diagnosed and treated in the Maria Skłodowska-Curie Institute and Oncology Centre, Warsaw, Poland and the Medical University of Warsaw, Poland in the years 2002-2013. The control group consisted of 28 patients with CD5-negative DLBCL. CD5-positive DLBCL accounted for 6.26% of all DLBCL cases diagnosed in the Maria Skłodowska-Curie Institute and Oncology Centre in the years 2008-2012. The incidence is comparable to other European countries, lower than noted in Japan and higher than in the US. Patients with CD5-positive DLBCL, in comparison to the CD5-negative group, were characterized by: (1) older age (≥ 60 vs. younger) and worse general status (ECOG ≥ 2 vs. < 2), (2) lower frequency of complete remission (CR), (3) higher expression of unfavorable prognostic factors (BCL2, FOXP1, CD44) and MMP-9, and (4) lower expression of favorable prognostic factors (CD30, cyclin D1, cyclin D3) and TIMP-2.
REFERENCES (54)
1.
Friedberg JW. Diffuse Large B-Cell Lymphoma. Hematol Oncol Clin North Am 2008; 22: 941-949.
2.
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. IARC Press, Lyon 2008; 9-15.
3.
Chan AC, Chan JK. Diffuse Large B-cell Lymphoma. In: Hematopathology. Jaffe ES, Harris NL, Vardiman JV, et al. (eds.). Saunders Elsevier, Philadelphia 2011; 349-381.
4.
Zheng Y, Ma XB, Jiang J, et al. CD5 expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Zhonghua Binglixue Zazhi 2012; 41: 156-160.
5.
Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008; 19: 1921-1926.
6.
Niitsu N, Okamoto M, Tamaru J, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol 2010; 21: 2069-2074.
7.
Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013; 121: 2715-2724.
8.
Bodoor K, Matalka I, Hayajneh R, et al. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis. Asian Pac J Cancer Prev 2012; 13: 3037-3046.
9.
Yoon DH, Choi DR, Ahn HJ, et al. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. Eur J Haematol 2010; 85: 149-157.
10.
Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005; 18: 1377-1384.
11.
Tzankov A, Pehrs AC, Zimpfer A, et al. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol 2003; 56: 747-752.
12.
Leroy K, Haioun C, Lepage E, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002; 13: 1108-1115.
13.
Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, et al. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur J Haematol 2009; 82: 364-372.
14.
Schuetz JM, Johnson NA, Morin RD, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 2012; 26: 1383-1390.
15.
Song MK, Chung JS, Shin DH, et al. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP. Leuk Lymphoma 2009; 50: 54-61.
16.
Xu Y, McKenna RW, Molberg KH, et al. Clinicopathologic analysis of CD10+ and CD10– diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol 2001; 116: 183-190.
17.
Shin HJ, Chung J, Park DY, et al. Prognostic significance of the cyclin D3 and the Ki-67 expression for predicting clinical outcome in diffuse large B-cell lymphoma. J Clin Oncol 2004; 22 (Suppl): 6714.
18.
Gumina MR, Xu C, Chiles TC. Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth. Evidence for redundancy with cyclin E. Cell Cycle 2010; 9: 820-828.
19.
Barrans SL, Fenton JA, Banham A, et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004; 104: 2933-2935.
20.
Xu Y, McKenna RW, Molberg KH, et al. Clinical relevance of CD10 expression in de novo large B-cell lymphoma. Mod Pathol 2000; 13: 166.
21.
Fabiani B, Delmer A, Lepage E, et al. CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Archiv 2004; 445: 545-551.
22.
Ohshima K, Kawasaki C, Muta H, et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39: 156-162.
23.
Zhou K, Xu D, Cao Y, et al. C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: A meta-analysis of epidemiological studies. PLoS One 2014; 9: 950-920.
24.
Olarte I, Martinez A, Ramos-Penafiel C, et al. MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Hematology 2011; 16: 368-372.
25.
Ma XB, Zheng Y, Yuan HP, et al. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis. Hum Pathol 2015; 46: 593-599.
26.
Boussiotis VA. Cell-specific PD-L1 expression in DLBCL. Blood 2015; 126: 2171-2172.
27.
Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry. Circ Res 2003; 92; 827-839.
28.
Fink K, Boratyński J. The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis. Postepy Hig Med Dosw (Online) 2012; 66; 609-628.
29.
Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
30.
Löffek S, Schilling O, Franzke CW. Biological role of matrix metalloproteinases: a critical balance. Eur Respir J 2011; 38: 191-208.
31.
Malaponte G, Hafsi S, Polesel J, et al. Tumor microenvironment in diffuse large B-cell lymphoma: Matrix metalloproteinases activation is mediated by osteopontin overexpression. Biochim Biophys Acta 2016; 1863: 483-489.
32.
Pennanen H, Kuittinen O, Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma. Eur J Haematol 2008; 80: 46-54.
33.
Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138-140.
34.
Kroft SH, Howard MS, Picker LJ, et al. De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma. Hematopathology 2000; 114: 523-533.
35.
Linderoth J, Jerkeman M, Cavallin-Ståhl E, et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma. A Nordic Lymphoma Group Study. Clin Cancer Res 2003; 9: 722-728.
36.
Ogawa S, Yamaguchi M, Oka K, et al. CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival. Br J Haematol 2004; 125: 180-186.
37.
Jain P, Fayad LE, Rosenwald A. Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol 2013; 88: 798-802.
38.
Wlodarska I, Veyt E, De Paepe P. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005; 19: 1299-1305.
39.
DeLisser HM. CD44: target for antiangiogenesis therapy. Blood 2009; 114: 5114-5115.
40.
Inagaki H, Banno S, Wakita A, et al. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma. Mod Pathol 1999; 12; 546-552.
41.
Cao Y, Langer R. A review of Judah Folkman’s remarkable achievements in biomedicine. Proc Natl Acad Sci U S A 2008; 105: 13203-13205.
42.
Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999; 237: 1-30.
43.
Zhu J, Diao Y, Jiang M. Significance of expression of VEGF in patients with diffused large B cell lymphoma. U.S. Chinese Journal of Lymphology and Oncology 2007; 6: 61-66.
44.
Gratzinger D, Zhao S, Tibshirani RJ. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008; 88: 38-47.
45.
Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-308.
46.
Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29: 290-308.
47.
Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP-3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9; 407-415.
48.
Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-637.
49.
Sakata KI, Satoh M, Someya M, et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 2004; 100: 356-365.
50.
Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-2323.
51.
Yoshida N, Oda M, Kuroda Y, et al. Clinical Significance of sIL-2R Levels in B-Cell Lymphomas. PLoS One 2013; 8: 1-10.
52.
Feng YH, Wu LS, Su J, et al. Expression and significance of MMP-26, TIMP-4 and MMP-9 in diffuse large B-cell lymphoma cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2013; 21: 1167-1172.
53.
Kyllönen H, Pasanen AK, Kuittinen O, et al. Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody. Leuk Lymphoma 2009; 50: 1301-1307.
54.
Fingleton B. MMP Inhibitor Clinical Trials – The Past, Present, and Future. In: The Cancer Degradome. Edwards D, et al (eds.). Springer Science + Business Media, LLC 2008; 759-785.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
